Unknown PHASE2 INTERVENTIONAL 1-arm NCT04718584

the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors

A Single-arm, Open, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) in the Treatment of Urinary and Male Genital Tumors

Sponsor: Dragonboat Biopharmaceutical Company Limited

Conditions Advanced Penile Carcinoma Bladder Cancer Renal Carcinoma

Interventions Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)

Updated 4 times since 2021 Last updated: Jan 17, 2021 Started: Sep 11, 2020 Primary completion: Nov 30, 2022 Completion: Nov 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Advanced Penile Carcinoma and Bladder Cancer, this trial is ongoing. The trial is conducted by Dragonboat Biopharmaceutical Company Limited and has accumulated 4 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Dec 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Feb 2021 — Dec 2023 [monthly]

Recruiting PHASE2

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dragonboat Biopharmaceutical Company Limited
Fudan University

Data source: Dragonboat Biopharmaceutical Company Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China